Press Releases OptiNose, Inc.

Equities

OPTN

US68404V1008

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
1.17 ^USD	-4.10%		+2.63%	-9.30%

05-09	OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	CI
04-25	OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Optinose Announces Reporting Date for First Quarter 2024 Financial Results	05-10	AQ
Optinose Announces $55 Million Registered Direct Offering	05-09	AQ
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	04-25	AQ
Optinose to Present at the Needham Virtual Healthcare Conference	04-04	AQ
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	03-15	AQ
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	03-14	PR
OptiNose: Q4 Earnings Snapshot	03-07	AQ
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	03-07	AQ
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results	02-29	AQ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice	01-18	AQ
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	12-06	AQ
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference	11-22	AQ
OptiNose: Q3 Earnings Snapshot	11-09	AQ
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates	11-09	AQ
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results	27/10/23	AQ
Optinose to Present at the 2023 Cantor Global Healthcare Conference	22/09/23	AQ
OptiNose: Q2 Earnings Snapshot	10/08/23	AQ
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates	10/08/23	AQ
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million	27/07/23	AQ
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	16/06/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OptiNose, Inc.

Equities

OPTN

US68404V1008

Press Releases

Filters